Picture of Heartseed logo

219A Heartseed Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-5.71%
3mn/a
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-14.58%
50d MA+3.24%
200d MA+3.24%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-23.23%
Return on Equity-27.21%
Operating Margin-423.41%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Oct 202431st Oct 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Heartseed EPS forecast chart

Profile Summary

Heartseed Inc is a Japan-based company engaged in research and development of regenerative medicine products. The Company has established cardiac regenerative medicine, a therapy in which microtissue (cardiomyocytes) derived from iPS cells are transplanted into the heart, and conducts business activities for patients with severe heart failure. Target diseases include dilated cardiomyopathy (DCM), old myocardial infarction (OMI), and dilated-phase hypertrophic cardiomyopathy (D-HCM). Except the pipeline's leading cardiac treatment HS-001 (administration of regenerated myocardium derived from allogeneic iPS cells to the myocardium), the Company also conducts research into the creation of myocardium using autologous iPS cells that do not pose immune rejection reactions and iPS cells with HLA knockout.

Directors

    Last Annual
    October 31st, 2023
    Last Interim
    July 31st, 2024
    Incorporated
    November 30th, 2015
    Public Since
    July 30th, 2024
    No. of Employees
    39
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    jp flag iconTokyo Stock Exchange
    Shares in Issue
    22,225,400

    219A Share Price Performance

    Upcoming Events for 219A

    Dividend For 219A.T - 0.0000 JPY

    Similar to 219A

    Picture of 3-D Matrix logo

    3-D Matrix

    jp flag iconTokyo Stock Exchange

    Picture of AnGes logo

    AnGes

    jp flag iconTokyo Stock Exchange

    Picture of BrightPath Biotherapeutics Co logo

    BrightPath Biotherapeutics Co

    jp flag iconTokyo Stock Exchange

    Picture of Carna Biosciences logo

    Carna Biosciences

    jp flag iconTokyo Stock Exchange

    Picture of Chiome Bioscience logo

    Chiome Bioscience

    jp flag iconTokyo Stock Exchange

    FAQ